These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 18360826

  • 1. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
    Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L, Rodarte C, Smythe WR.
    Int J Cancer; 2008 Jul 01; 123(1):202-8. PubMed ID: 18360826
    [Abstract] [Full Text] [Related]

  • 2. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, Smythe WR.
    Mol Cancer Ther; 2004 May 01; 3(5):545-50. PubMed ID: 15141012
    [Abstract] [Full Text] [Related]

  • 3. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, Berta J, Kubista B, Dome B, Grusch M, Setinek U, Micksche M, Klepetko W, Berger W.
    J Thorac Oncol; 2011 May 01; 6(5):852-63. PubMed ID: 21358348
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J.
    Cancer Sci; 2010 Sep 01; 101(9):1955-64. PubMed ID: 20608936
    [Abstract] [Full Text] [Related]

  • 5. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
    Hopkins-Donaldson S, Cathomas R, Simões-Wüst AP, Kurtz S, Belyanskaya L, Stahel RA, Zangemeister-Wittke U.
    Int J Cancer; 2003 Aug 20; 106(2):160-6. PubMed ID: 12800189
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
    Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S.
    Lung Cancer; 2007 Jun 20; 56(3):327-36. PubMed ID: 17383050
    [Abstract] [Full Text] [Related]

  • 9. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.
    Mol Cancer Ther; 2016 Oct 20; 15(10):2357-2369. PubMed ID: 27512118
    [Abstract] [Full Text] [Related]

  • 10. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
    Masui T, Hosotani R, Ito D, Kami K, Koizumi M, Mori T, Toyoda E, Nakajima S, Miyamoto Y, Fujimoto K, Doi R.
    Surgery; 2006 Aug 20; 140(2):149-60. PubMed ID: 16904964
    [Abstract] [Full Text] [Related]

  • 11. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S.
    Respirology; 2012 Aug 20; 17(6):984-90. PubMed ID: 22574723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, Bastianutto C, Liu FF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8131-44. PubMed ID: 16299246
    [Abstract] [Full Text] [Related]

  • 16. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
    Onen HI, Yilmaz A, Alp E, Celik A, Demiroz SM, Konac E, Kurul IC, Menevse ES.
    Hum Exp Toxicol; 2015 Feb 15; 34(2):117-26. PubMed ID: 25028262
    [Abstract] [Full Text] [Related]

  • 17. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME.
    BJU Int; 2006 Jun 15; 97(6):1300-8. PubMed ID: 16686729
    [Abstract] [Full Text] [Related]

  • 18. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM.
    BMC Cancer; 2015 May 08; 15():374. PubMed ID: 25952930
    [Abstract] [Full Text] [Related]

  • 19. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O, Tschopp S, Olie RA, Leech SH, Simões-Wüst AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U.
    J Natl Cancer Inst; 2001 Mar 21; 93(6):463-71. PubMed ID: 11259472
    [Abstract] [Full Text] [Related]

  • 20. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
    Smythe WR, Mohuiddin I, Ozveran M, Cao XX.
    J Thorac Cardiovasc Surg; 2002 Jun 21; 123(6):1191-8. PubMed ID: 12063468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.